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Therefore an oral formulation of IP (500 mg crystallized IP in hard gelatine capsules) was developed. The bioavailability of the oral IP formulation was investigated in 18 patients with bronchogenic carcinoma. Oral and i.v. IP were applicated in a randomized sequartz on day 1 and 3 at a dose of 1 g/sqm and 2 g/sqm. IP determination was performed with N/P flame ionization gas chromatography after derivatization with heptaflnorobutyric (Wagner,T., Fenneberg,K., Arzneim. Forsch.34,313,1984) . Oral administered IP showed a relatively fast absorption kinetic. Peak levels were reached Within one hour in both dosage groups. This also points to a fast drug releasefrom the gelatine capsules used in our study. With exception of the absorption phase blood level curves of oral and i.v. administered IP was identical. The average half-life of IP was 5.5 hrs after 2 g/sqm and 5.8 hrs at a dose of i g/sqm IP with a great individual variation in both dosage groups. Oxazaphosphorine cytostatics such as cyclophosphamide (CP) and ifosfamide (IP) require enzymatic activation to develop their alkylatingproperties. In man more than 80% of CP is metabolized and the half-life of CP mainly depends on the activation rate in the liver (Wagner,T. et al.,Cancer Res. Clin. 0ncoi.96,79,1980) . In our study in 4 patients with severe aplastic anemia who received 50 mg/kg for 4 days as a conditioning treatment for bone marrow transplantation,CPhalflife was shortened from 7,3• to 4,3• during treatment. In 7 leukemic patients (60mg/kgx 2) half-life decreased from 4,7"1,3 hrs on day 1 to 3,010,4 on day 2. Since the peak levels of activated metabolites at the same time were enhanced and urinary excretion of the parent drug di d not c~mnge significantly, the shortening of CP half-life is obviously due to a selfinduction of CP activation in the liver. Results of selfinduction of CPmetabolismwere confirmedinanimal studies (NMRI mice). Similar observations on a shortening of drug half-life only to a smaller extent, were made for IPmetabolism in man. During treatment of bronchogenic carcinoma with 2 g/sqm in 6 patients a decrease of IP half-life from 6,4 • hrs on day 1 to 5,4• after the second dose on day 3wasmeasured. At a dose of 1 g/sqm IP(n=12) IPhalf-lifewas shortened from 6,4• to 5,3• hrs. In CP treatment of breast cancer in 12 patients at a low dosage range of 175mg/sqm no change in CP half-life could be detected during drug a&ti-nistration on four consecutive days (4,16/4,01/4,14/3,95hr~. Thus, acceleration of CP and IP metabolism during short-time treatment occured only within a high dosage range. Theremarkable influence of repeated high dose application of CPand IP on their metabolism may result inadifferent drug toxicity and tumour response. ]he aim of this study was to examine the possible interaction between ifosfamide and mema~. 27 patients with advanced or metastatic soft tissue sarcoma not suitable2for surgery or radiation were treated with high dose ifosfamide (5 g/m ) and concomitant ~.Tne histopathological diagnoses were:anclassified soft tissue sarcoma 9, leiomyosarccam 6, epitheloid cell sarcoma 2, fibresarr 2, malignant fibrous histiocytccna 2, angiosercoma 2, malignant giant cell ttm~ur i, synovial cell sarcoma 1 and n~ignant schwannoma i. 15 patients were males. 12 females.Median age was 42 years (range 17 -72 years). Median Karnovsky index was 60 %.17 patients bed received prior chemotherapy (CYVADIC). Median time of potentJal follow up was 21 months. the uroprotective agent mesoa was gives ~ t~ different ways.Group A:LOW dose i.v. bolus injection 400 m~ni every 4 hrs to a total of doses or to the urine being free of erythrocytes (total dose 2.8 g~ ). Group B:High dose infusion:] ~our before ifosfamide infusion 1 g/m was infused followed by 5 o~m concomitant with ifes~amide followed by hO0 m~m ~ every 4 hrs for 24 hrs (total dose 8.8 g/m ). 17 pts ware treated with ifesfa~ide and low dose mesna receiving a total of 55 courses, i0 pts received ifasfanide with high dose mesna. Total ntmler of courses in this group was 21. 4 pts achieved a partial response (14.8 %). 3 of these bed had prior chemotherapy. No change was observed in 14 pts.Duration of response was 3 -13 months. Median survival was 8 months.AIL RESPONDERS WERE IN GROUP A. In this group ii courses was followed by microscopical hematuria.3 courses were followed by infectious. Anemia developed after 3 courses.In group B 3 courses were followed by hematuria.No infections or anemla were observed.T~e effect of administering either ifosfamide or ifosfmrXde and mesua on the lifespan of L1210 tt~rour-bearing DBA/2 mice was studied.lncreesing the dose of ifosfamide frcm 80 m~kg to 240 mg/kg caused an increase in crease in lifespan ccfnpared with non-treated animals from 40 % to I00 %. When maena was added i6 the same dose as ifosfamide this increase was lowered to 15 and 58 % respectively.This dearly shows that mesa~ may interfere with ifosfamide in an experimental system. ]he uroprotective agent should therefore be used at the lowest possible dose that prevents urothelial damage. Further studies into the optimal use of mesrm /ifosfamide is clearly needed.
